Increased CD36 protein as a response to defective insulin signaling in macrophages

Journal of Clinical Investigation

Volumn 113, Issue 5, 2004, Pages 764-773

  Liang, Chien Ping ^a   Han, Seongah ^a   Okamoto, Haruka ^a   Carnemolla, Ronald ^a   Tabas, Ira ^a   Accili, Domenico ^a   Tall, Alan R ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CD36 ANTIGEN; INSULIN; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTIDIABETIC AGENT; CELL RECEPTOR; CHROMONE DERIVATIVE; ENZYME INHIBITOR; GLUTATHIONE; MORPHOLINE DERIVATIVE; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR; TYROSINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DEATH; FOAM CELL; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; MORBIDITY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETIC TRANSCRIPTION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NORTHERN BLOTTING; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD36; BLOTTING, NORTHERN; BLOTTING, WESTERN; CHROMONES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; FOAM CELLS; GLUTATHIONE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, OBESE; MORPHOLINES; OXYGEN; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TYROSINE;

EID: 85047690709     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19528     Document Type: Article

References (55)

1. Haffner, S.M., Lehro, S., Ronnemaa, T., Pyorala, K., and Laakso, M. 1998. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med 339:229-234.
2. Ginsberg, H.N. 2000. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106:453-458.
3. Reaven, G.M. 2002. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes. Metab. 4:S13-S18.
4. Haffner, S.M. 2002. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am. J. Cardiol. 90:55i-61i.
5. Steinberg, H.O., and Baron, A.D. 2002. Vascular function, insulin resistance and fatty acids. Diabetologia. 45:623-634.
6. Vicent, D., et al. 2003. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111:1373-1380. doi: 10.1172/JC1200315211.
7. Bar, R.S., Kahn, C.R., and Koren, H.S. 1977. Insulin inhibition of antibody-dependent cytoxicity and insulin receptors in macrophages. Nature. 265:632-635.
8. Li, A.C., et al. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106:523-531.
9. Collins, A.R., et al. 2001. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21:365-371.
10. Chen, Z., et al. 2001. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21:372-377.
11. Lee, C-H., and Evans, R.M. 2002. Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis. Trends Endocrinol. Metab. 13:331-335.
12. Moore, K.J., et al. 2001. The role of PPAR-α in macrophage differentiation and cholesterol uptake. Nat. Med. 7:41-47.
13. Chawla, A., et al. 2001. A PPAR gamma LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7:161-171.
14. Chinetti, G., et al. 2001. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7:53-58.
15. Akiyama, T.E., et al. 2001. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22:2607-2619.
16. Claudel, T., et al. 2001. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. U. S. A. 298:2610-2615.
17. Reitman, M.L. 2000. Rodent genetic models of obesity and type 2 diabetes mellitus. In Diabetes mellitus: a fundamental and clinical text. 2nd edition. D. LeRoith, S.I. Taylor, and J.M. Olefsky, editors. Lippincott Williams & Wilkins Publishers. Philadelphia, Pennsylvania, USA. 723-734.
18. Hasty, A.H., et al. 2001. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem. 276:37402-37408.
19. Accili, D., et al. 1996. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12:106-109.
20. Okamoto, H., Nakae, J., Kitamura, T., Park, B.-C., and Accili, D. 2002. Prevention of diabetes in mice lacking insulin receptors requires restoration of insulin action in liver, pancreatic beta cells and brain. Diabetes. 51:A328.
21. Chen, W., et al. 2001. Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux: from late endosomes/lysosomes. J. Biol. Chem. 276:43564-43569.
22. Graziani-Bowering, G.M., Graham, J.M., and Filion, L.G. 1997. A quick, easy and inexpensive method for the isolation of human peripheral blood monocytes. J. Immunol. Methods. 207:157-168.
23. Goldstein, J.L., Basu, S.K., and Brown, M.S. 1983. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98:241-260.
24. Sakr, S.W., et al. 2001. The uptake and degradation of matrix-bound lipoproteins by macrophages require an intact actin cytoskeleton, Rho family GTPases, and myosin ATPase activity. J. Biol. Chem. 276:37649-37658.
25. Kunjathoor, V.V., et al. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277:49982-84998.
26. Hannah, V.C., Ou, J., Luong, A., Goldstein, J.L., and Brown, M.S. 2001. Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells. J. Biol. Chem. 276:4365-4372.
27. 2-adrenergic receptors does not require agonist-elicited endocytosis. J. Biol. Chem. 274:24935-24940.
28. Liang, C.P., and Tall, A.R. 2001. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276:49066-49076.
29. Krieger, M., and Herz, J. 1994. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biocbem. 63:601-637.
30. Knutson, V.P., Donnelly, P.V., Balba, Y., and Lopez-Reyes, M. 1995. Insulin resistance is mediated by a proteolytic fragment of the insulin receptor. J. Biol. Chem. 270:24972-24981.
31. Saltiel, A.R., and Kahn, C.R. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414:799-806.
32. Peraldi, P., Xu, M., and Spiegelman, B.M. 1997. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J. Clin. Invest. 100:1863-1869.
33. Chao, L., et al. 2000. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106:1221-1228.
34. Febbraio, M., Hajjar, D.P., and Silverstein, R.L. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest 109:785-791. doi:10.1172/JCI200114006.
35. Bar, R.S., Gorden, P., Roth, J., Kahn, C.R., and De Meyts, P. 1976. Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting. J. Clin. Invest. 58:1123-1135.
36. Welham, M.J., et al. 1997. Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells. J. Biol. Chem. 272:1377-1381.
37. Frittitta, L., Grasso, G., Munguira, M.E., Vigneri, R., and Trischitta, V. 1993. Insulin receptor tyrosine kinase activity is reduced in monocytes from nonobese normoglycaemic insulin-resistant subjects. Diabetologia. 36:1163-1167.
38. Zoppini, G., Galante, P., Zardini, M., and Muggeo, M. 1994. Phosphotyrosine protein profiles in monocytes after insulin and IGF-1 stimulation. Eur. J. Clin. Invest. 24:275-278.
39. Malide, D., Davies-Hill, T.M., Levine, M., and Simpson, I.A. 1998. Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation. Am. J. Physiol. 274:E516-E526.
40. Laffitte, B.A., et al. 2003. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl Acad. Sci U. S. A. 100:5419-5424.
41. Rosa, L.F., Cury, Y., and Curi, R. 1992. Effects of insulin, glucocorticoids and thyroid hormones on the activities of key enzymes of glycolysis, glutaminolysis, the pentose-phosphate pathway and the Krebs cycle in rat macrophages. J. Endocrinol. 135:213-219.
42. Berg, A.H., Combs, T.P., Du, X., Brownlee, M., and Scherer, P.E. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947-953.
43. Fruebis, J., et al. 2001. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98:2005-2010.
44. Maeda, N., et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8:731-737.
45. Steppan, C.M., et al. 2001. The hormone resistin links obesity to diabetes. Nature. 409:307-312.
46. Griffin, E., et al. 2001. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat. Med. 7:840-846.
47. Sampson, M.J., Davies, I.R., Braschi, S., Ivory, K., and Hughes, D.A. 2003. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis. 167:129-134.
48. Kako, Y., Masse, M., Huang, L.S., Tall, A.R., and Goldberg, I.J. 2002. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J. Lipid Res. 43:872-877.
49. Reaven, P., Merat, S., Casanada, F., Sutphin, M., and Palinski, W. 1997. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 17:2250-2256.
50. Febbraio, M., et al. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest 105:1049-1056.
51. Podrez, E.A., et al. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277:38517-38523.
52. Linton, M.F., and Fazio, S. 2001. Class A scavenger receptors, macrophages, and atherosclerosis. Curr. Opin. Lipidol. 12:489-495.
53. Koshiyama, H., Shimono, D., Kuwamura, N., Minamikawa J., and Nakamura, Y. 2001. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 86:3452-3456.
54. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:79-82.
55. Welch, J.S., Ricote, M., Akiyama, T.E., Gonzalez, FJ., and Glass, C.K. 2003. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100:6712-6717.